Civik Thomas 4
4 · Pyxis Oncology, Inc. · Filed Mar 28, 2024
Insider Transaction Report
Form 4
Civik Thomas
DirectorInterim CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-03-26$3.83/sh+44,024$168,612→ 44,024 totalExercise: $3.83Exp: 2034-03-26→ Common Stock (44,024 underlying)
Footnotes (1)
- [F1]The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.